Better volumes, but payor mix matters
- DaVita makes most of its money from dialysis treatments paid for by Medicare, Medicaid, and commercial insurance.
- Q1 2026 was strong enough for management to raise adjusted EPS guidance to $14.10 to $15.20.
- Treatment volume is now expected to grow 25 to 50 basis points for 2026, helped by patient transfers and lower mortality.
- The key weakness is payor mix, because commercial plans pay much more than government programs.
- Share buybacks can lift EPS, but DaVita also carries a heavy debt load and must keep cash flowing.
The setup improved, not cleared
DaVita entered 2026 with better momentum than expected. After Q1, management raised adjusted EPS guidance to $14.10 to $15.20 and raised 2026 treatment volume growth expectations from flat to 25 to 50 basis points. The 10-Q backed up the call: treatment volumes beat expectations because patient census was better, helped by lower mortality and more patient transfers, partly offset by weaker new admissions.
The bull case is simple. Dialysis is a needed service, volume trends are improving, and labor productivity was better than expected in Q1. If those gains hold, DaVita can offset cost inflation and use share repurchases to grow EPS faster than the business itself grows.
The bear case is also clear. Q1 revenue per treatment may have been helped by timing. Management said commercial mix should decline through 2026, which would pressure revenue per treatment and could make the 1% to 2% full-year target harder to hit. The stock needs DaVita to keep volumes, payor mix, costs, and buybacks all working at the same time.
Paid by the treatment
DaVita provides kidney dialysis, mostly in outpatient centers. A patient comes in for treatment, DaVita bills a payor, and the company earns revenue per treatment. The main payors are Medicare, Medicaid, Medicare Advantage, and commercial insurance.
The most important detail is the payor mix. Commercial insurance pays far more than government programs, so a small shift away from commercial patients can hurt profit. This is why ACA enrollment, bronze plan selection, and commercial mix commentary matter so much.
DaVita is also building Integrated Kidney Care, or IKC. In IKC, DaVita tries to manage the full cost and quality of care for kidney patients, not just provide dialysis. That can create upside if care is managed well, but it adds contract and medical-cost risk.
Kidney care pieces
U.S. in-center hemodialysis
This is the core business. It provides recurring dialysis treatments in DaVita clinics and drives most revenue and operating profit.
Related lab services
Lab services support dialysis care and sit inside the U.S. dialysis business. They add scale around the main treatment network.
Oral phosphate binders
These drugs are now part of the Medicare dialysis benefit. They create a new revenue stream, but also bring new drug cost and reimbursement risk.
Integrated Kidney Care
IKC is DaVita's value-based care business. It became profitable in 2025, one year ahead of plan, but reported a Q1 2026 operating loss that management said was expected.
International dialysis clinics
DaVita operates clinics outside the United States and continues to look at acquisitions. Q1 2026 international revenue rose versus the prior year, helped by acquired growth.
Other ancillary services
This bucket includes clinical research, transplant software, and venture investments. These are smaller than dialysis but could add useful services around kidney care.
One core segment dominates
Mix uses Q1 2026 external revenues from DaVita's 10-Q revenue table: U.S. dialysis at $2.921 billion and other ancillary services at $494 million. Other ancillary bundles IKC, international, and smaller U.S. ancillary lines, so it hides different profit profiles.
What could break the story
Commercial mix slips faster
High impact · Medium oddsDaVita earns much more from commercial insurance than from government programs. Management said commercial mix should decline through 2026, which can pressure revenue per treatment. Bronze ACA plans also create higher patient out-of-pocket costs, adding another headwind.
Volume gains fade
Medium impact · Medium oddsQ1 volume beat expectations because mortality was lower and patient transfers were higher. New admissions were weaker, which is a warning sign. If competitor closure benefits fade or admissions stay soft, the new 25 to 50 basis point growth target may be at risk.
Labor and supplies reaccelerate
High impact · Medium oddsDialysis is labor intensive, and DaVita has faced higher wage, insurance, medical supply, and IT costs. Q1 benefited from better labor productivity, but that may not repeat. If cost per treatment rises faster than revenue per treatment, margins can compress.
Policy changes hurt reimbursement
High impact · Medium oddsDaVita depends on Medicare, Medicare Advantage, Medicaid, and commercial plan rules. Changes to enhanced premium tax credits, Medicare ESRD rates, Medicare Advantage benchmarks, or charitable premium assistance rules could shift enrollment and payments. The 10-Q also flags OBBBA and federal policy changes as possible risks.
Debt and buybacks limit flexibility
Medium impact · Medium oddsDaVita uses a lot of debt and keeps buying back stock. At March 31, 2026, long-term debt was $10.5 billion and Q1 debt expense was $145 million. Buybacks help EPS, but they also use cash that could otherwise reduce leverage or fund growth.
In one breath
What does DaVita do?
DaVita provides dialysis for people with kidney failure. Most care happens in outpatient centers, where patients receive recurring treatments and DaVita bills Medicare, Medicaid, Medicare Advantage, or commercial insurance.
Why does commercial insurance matter so much for DaVita?
Commercial plans pay much more than government programs for dialysis. That means a small move in commercial mix can have a large effect on revenue per treatment and profit.
What changed after Q1 2026?
Management raised adjusted EPS guidance to $14.10 to $15.20 and raised treatment volume growth expectations to 25 to 50 basis points. The main concern is that commercial mix is still expected to decline later in 2026.
Is Integrated Kidney Care important?
Yes, but it is still smaller than core dialysis. IKC became profitable in 2025, one year ahead of plan, and is meant to manage total kidney care costs, but Q1 2026 still showed an operating loss in that line.